Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...
A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding ...
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback